Medicine information ESBRIET 267mg capsules
- Product code:
- W64377001
- Quantity:
- 63
- Indicated for:
- idiopathic pulmonary fibrosis
- Route of administration:
- oral
- Substance:
- pirfenidone (antifibrotic agent)
- ATC
- L04AX05 — Antineoplastic and immunomodulating agents | Immunosuppressants | Immunosuppressants | Other immunosuppressants
Pirfenidone is a medication used for the treatment of idiopathic pulmonary fibrosis (IPF), a chronic progressive disease affecting the lungs.
It works by reducing inflammation and the formation of scar tissue in the lungs, thereby slowing the progression of the disease.
Pirfenidone is administered as oral tablets, usually three times a day, with the dose gradually increased to minimize the risk of side effects.
The medication helps improve lung function and reduce symptoms such as shortness of breath and fatigue.
Common side effects include nausea, diarrhea, skin rashes, and increased sensitivity to sunlight.
Patients should avoid prolonged sun exposure and use sunscreen to prevent skin reactions.
It is important for patients to undergo regular liver function tests during treatment, as pirfenidone may affect the liver.
The medication is not recommended for pregnant or breastfeeding women without medical consultation.
General data about ESBRIET 267mg
- Substance:
- pirfenidone
- Date of latest medicines list:
- 01-03-2022
- Product code:
- W64377001
- Strength:
- 267mg
- Pharmaceutical form:
- capsules
- Quantity:
- 63
- Product type:
- Original
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for pirfenidone
Strengths available for pirfenidone
- 267mg
- 801mg
Official documents
The SmPC text is not displayed because a match to this medicine, strength and pharmaceutical form has not been confirmed.
The correspondence between the document and the displayed text is unconfirmed.
- Source institution
- EMA
- Document language
- English
- Source record: first published
- 11/03/2011
- Source record: last updated
- 10/07/2026